Three CSIR laboratories are jointly working on varied platforms to develop potential vaccines against the SARS-CoV-2 virus that causes Covid-19.
Rakesh Mishra, director of CSIR-Centre for Cellular and Molecular Biolgoy (CCMB) on Thursday said that the institute is working with two other CSIR labs in Kolkata and Chandigarh to develop potential Covid-19 vaccines, reports The Hindu.
Mishra said that the platforms that CCMB and other CSIR labs have been developing are slightly different from the vaccines currently under testing in the country. These vaccines will be based on 'pseudo virus' and 'pre-processed proteins', the CCMB director said.
"We are now testing them on mice, if they are responsive, we will give the technology to Aurobindo Pharma for making of vaccines,” Mishra was quoted as saying during the launch of ‘CoronaAID’ food supplement.
However, the CCMB director cautioned that an 'effective' vaccine against Covid-19 could be months or years away and even after the vaccine is launched, it could take months to vaccinate the 1.30 billion people across the country.
He further said that the efficacy of any vaccine could only be assessed over a course of time of several months or couple of years as it's effectiveness on people of different age groups cannot be predicted.
He also emphasised on the need for wearing a face mask, maintaining social distancing and practicing hand hygiene for safety against the Covid-19 virus.
As you are no doubt aware, Swarajya is a media product that is directly dependent on support from its readers in the form of subscriptions. We do not have the muscle and backing of a large media conglomerate nor are we playing for the large advertisement sweep-stake.
Our business model is you and your subscription. And in challenging times like these, we need your support now more than ever.
We deliver over 10 - 15 high quality articles with expert insights and views. From 7AM in the morning to 10PM late night we operate to ensure you, the reader, get to see what is just right.
Becoming a Patron or a subscriber for as little as Rs 999/year is the best way you can support our efforts.